Trending...
- Capacity Crunch for Cold Plating? Not Anymore
- New Article by Roy J. Meidinger – Examines Hidden Hidden Healthcare Kickbacks
- A New Initiative from Florida Gains Momentum Nationwide
YANTAI, China, June 5, 2024 ~ At the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024, RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its latest innovations in the field of global cancer treatment. The company presented major research results on its proprietary antibody drug conjugates (ADCs) Disitamab Vedotin (RC48) and RC88.
The innovative drugs were featured in one Clinical Science Symposium, five Poster presentations, and ten online Abstracts at ASCO 2024. These presentations covered multiple cancer types including gastric and bladder cancer, and gynecological tumors. The studies included both monotherapy and combination therapies.
Dr. Jianmin Fang, CEO of RemeGen, expressed his honor at presenting the company's latest research findings on an internationally renowned stage such as ASCO Annual Meeting 2024. He stated that this not only demonstrates RemeGen's leading position in the field of antibody-drug conjugates in China but also proves their commitment to continuing research efforts to provide effective treatment options for patients worldwide.
More on illi News
One of the highlights of RemeGen's presentations was an oral presentation at a Clinical Science Symposium by Professor Song Li from Qilu Hospital of Shandong University. The presentation was based on a randomized, controlled (RCT) multicenter, single-arm, Phase II trial investigating the efficacy of RemeGen's disitamab vedotin (RC48) combined with toripalimab and the oral fluoropyrimidine S-1 in first-line HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma.
In addition to this symposium, RemeGen also presented five posters at ASCO 2024. One of these posters, presented by Professor Sheng Xinan from Peking University Cancer Hospital, focused on the preliminary efficacy and safety results of RC48-C017, a Phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC). The interim results showed promising efficacy and a manageable safety profile in operable MIBC patients, supporting further investigation for disitamab vedotin plus toripalimab in this population.
More on illi News
Other poster presentations included a Phase II multi-center study on adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 expression, and a prospective, single-arm, single-center clinical study on disitamab vedotin combined with toripalimab in patients with advanced penile cancer who have progressed on treatment or are intolerant to cisplatin chemotherapy.
In addition to these presentations, RemeGen also had ten online abstracts accepted by ASCO. These abstracts reflected the results of their RC48 and RC88 drugs in bladder, breast, and GI cancers. This further demonstrates the company's prolific innovation in global cancer treatment.
RemeGen's participation at ASCO 2024 highlights their commitment to advancing cancer treatment options globally. With their innovative drugs and ongoing research efforts, they continue to make significant contributions to the field of oncology.
The innovative drugs were featured in one Clinical Science Symposium, five Poster presentations, and ten online Abstracts at ASCO 2024. These presentations covered multiple cancer types including gastric and bladder cancer, and gynecological tumors. The studies included both monotherapy and combination therapies.
Dr. Jianmin Fang, CEO of RemeGen, expressed his honor at presenting the company's latest research findings on an internationally renowned stage such as ASCO Annual Meeting 2024. He stated that this not only demonstrates RemeGen's leading position in the field of antibody-drug conjugates in China but also proves their commitment to continuing research efforts to provide effective treatment options for patients worldwide.
More on illi News
- Wall Street's New Obsession? Tradewinds Aims to Revolutionize the $8B Gentlemen's Club Industry with National Peppermint Hippo™ Strategy $TRWD
- Poised for Major Growth with Strategic Military Orders, Global Expansion, and Groundbreaking Underground Mining Initiative $RMXI
- XRP fever is coming again, WOA Crypto helps the new trend and earns tens of thousands of dollars a day
- Inflation Rebounds Under Tariff Shadow: Wall Street Veteran Kieran Winterbourne Says Macro Signals Matter More Than Market Sentiment
- Vine Prime Community Launches Investor Pathway Program to Build Structured Investor Growth
One of the highlights of RemeGen's presentations was an oral presentation at a Clinical Science Symposium by Professor Song Li from Qilu Hospital of Shandong University. The presentation was based on a randomized, controlled (RCT) multicenter, single-arm, Phase II trial investigating the efficacy of RemeGen's disitamab vedotin (RC48) combined with toripalimab and the oral fluoropyrimidine S-1 in first-line HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma.
In addition to this symposium, RemeGen also presented five posters at ASCO 2024. One of these posters, presented by Professor Sheng Xinan from Peking University Cancer Hospital, focused on the preliminary efficacy and safety results of RC48-C017, a Phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC). The interim results showed promising efficacy and a manageable safety profile in operable MIBC patients, supporting further investigation for disitamab vedotin plus toripalimab in this population.
More on illi News
- Mensa Foundation's New Science Program Encourages Hands-On Discovery
- Golden Paper Introduces TAD Hand Towel Technology, Ushering in a New Era of Premium Tissue Quality
- ReedSmith® Creates Founder-Investor Connections at The Investor Dating Game™ by Tech Coast Venture Network During LA Tech Week
- OfficeSpaces.co Expands Its AI-Powered Website Builder Across North America
- Tobu Railway Group Will Host the Fourth Annual "Take-Akari" Bamboo Lantern Festival in East Tokyo, November 7, 2025 – January 31, 2026
Other poster presentations included a Phase II multi-center study on adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 expression, and a prospective, single-arm, single-center clinical study on disitamab vedotin combined with toripalimab in patients with advanced penile cancer who have progressed on treatment or are intolerant to cisplatin chemotherapy.
In addition to these presentations, RemeGen also had ten online abstracts accepted by ASCO. These abstracts reflected the results of their RC48 and RC88 drugs in bladder, breast, and GI cancers. This further demonstrates the company's prolific innovation in global cancer treatment.
RemeGen's participation at ASCO 2024 highlights their commitment to advancing cancer treatment options globally. With their innovative drugs and ongoing research efforts, they continue to make significant contributions to the field of oncology.
Filed Under: Business
0 Comments
Latest on illi News
- The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague
- TKL Group's New Factory Commences Production, Pioneering A New Era In Global Heavy Duty Truck Parts
- Regulated Crypto Exchange TZNXG Addresses Core US Market Challenges with Compliance-First Infrastructure
- Unleash Your Inner Seduction at HandPickedSC.com's "The Hot & The Wicked Halloween Soirée"
- GitKraken Launches Insights to Help Engineering Leaders Quantify AI Impact and Improve Developer Experience
- ZapperBox NextGen TV Gateway Receiver Now Testing Support For Secure Whole-Home Content Distribution
- Life as a Dog: P-Wave Press Brings Readers a Heartwarming Memoir of Love, Laughter and Companionship
- NOYA Launches Premium, Design-Forward Training Gear That Belongs at the Center of Your Space
- Research Defense Examines Violence, Illiteracy, Non-Active Fathers, and Low Self-Esteem Among Males
- Investing in Greece: Your Definitive Real-Estate FAQ Guide
- Mayor Brandon Johnson & World Business Chicago Host Chicago Consular Corps Diplomatic Roundtable
- KeysCaribbean Offers 20 Percent Off Seven-Night Stays For Private Home Collection Properties
- Advancing Circular Economy in Automotive ESD Packaging
- Institute for Pet Health Sciences Names Boops Pets 2025 Product of the Year
- Medcor Expands Telemedicine Access with Telecare Anywhere
- Matthew Cossolotto, Author of The Joy of Public Speaking, Appears on "Get Authentic with Marques Ogden" and "Achieving Success with Olivia Atkin"
- CCHR Exposes Conflicted Psychiatrists Behind Teen Antidepressant Surge
- Chicago: O'Hare Marks Busiest Summer Ever, Surpassing Pre-Pandemic Peak For The Season
- WIBO Announces Fall 2025 Entrepreneurship Programs to Empower NYC Founders and Small Business Owners
- Home Equity Theft: How Small Debts Are Costing Americans Their Homes